Yvonne McGrath
Chief Tech/Sci/R&D Officer bij ITEOS THERAPEUTICS, INC.
Vermogen: 422 840 $ op 31-03-2024
Actieve functies van Yvonne McGrath
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ITEOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-05-2020 | - |
Loopbaan van Yvonne McGrath
Eerdere bekende functies van Yvonne McGrath
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Director/Board Member | 01-05-2014 | 01-04-2020 |
| Chief Tech/Sci/R&D Officer | 01-05-2014 | 01-04-2020 | |
| IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 01-01-2010 | 01-04-2014 |
Opleiding van Yvonne McGrath
| The University of Wales | Doctorate Degree |
| Queen’S University Belfast | Undergraduate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 4 |
| België | 2 |
| Verenigde Staten | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ITEOS THERAPEUTICS, INC. | Health Technology |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
- Beurs
- Insiders
- Yvonne McGrath
- Ervaring
